Labopharm’s marketing partner for South Korea, WhanIn Pharmaceutical launched the product under the brand name TramaConti CR and its marketing partner for Australia, iNova Pharmaceuticals, launched the product under the brand name Durotram XR.
Labopharm’s marketing partner for Romania and Austria, CSC Pharmaceuticals, launched the product under the brand name Noax Uno.
Labopharm’s product is available in 100mg, 200mg and 300mg dosage strengths in Australia, Austria and Romania and in 100mg and 200mg dosage strengths in South Korea. The 300 mg dosage strength is approved for sale in South Korea and may be marketed at a later date.
James Howard-Tripp, president and CEO of Labopharm, said: “With these launches, our once-daily tramadol product is now being sold in 14 countries that combined, account for almost 55% of the world’s market for tramadol products.”